Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
N/A N=10 Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
Phase 2 N=75 Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Phase 2 N=27 Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
N/A N=163 New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Alzheimer Disease · Behavioral Disorders · Cognitive Impairment
Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1
N/A N=10 tACS for Amyloid-β Reduction in Alzheimer's Disease
Alzheimer Disease
Primary: Change in Amyloid Burden — -1.55 dSUVR
Phase 3 N=1,169 Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Cognition Disorders
Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260
N/A N=66 Care Coordination System for People With Dementia
Alzheimer Disease · Dementia · Dementia Alzheimers
Primary: Change in Baseline Burden and Stress of Caregivers Over 3 Months — -52.0; -31.9 percentage change
Phase 3 N=1,537 Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134
Phase 3 N=402 DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
Alzheimer's Disease
Primary: Rate of Change on the ADAS-Cog 11. — 7.98; 8.27 ADAS points per year
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
N/A N=45 Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer's Disease · Frontotemporal Dementia, Behavioral Variant
Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
Phase 2 N=80 Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline (Day 1) in Global and Regional Indices of Cerebral Metabolic Rate of Glucose (CMRglu) at Month 12 — -0.2793; -0.0887; -0.3143; -0.0786 Milligrams…
Phase 2 N=100 The Synapse Project
Alzheimer Disease
Primary: ROC AUCs (MCI/AD vs Cognitively Unimpaired (CU)) for Medial Temporal Lobe (MTL) UCB-J Distribution Volume Ratio (DVR) and Hippocampal Volume — 0.79; 0.81 probability…
Phase 2 N=22 Alzheimer's Disease Acitretin Medication
Alzheimer Disease
Primary: Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline — 1.251; 0.8741 fold change…
Early Phase 1 N=32 A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
Alzheimer Disease
Primary: Mean Cortical to Cerebellum SUVR — 1.665; 1.246 SUVR
Phase 2 N=50 Riluzole in Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
Phase 2 N=65 Alzheimer's Disease: Potential Benefit of Isoflavones
Alzheimer's Disease
Primary: Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min — 21.5; 25.7 number of words generated per minute
Phase 2 N=128 Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236
Phase 2 N=124 Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Mild Cognitive Impairment · Alzheimer Disease
Primary: Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) — 0.12; 3.27 OD — p=<0.0001
Early Phase 1 N=12 Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
Alzheimer Disease
Primary: Microglial Activation Reserve Index (MARI) — 17.7; 30.1 percentage of MARI — p=0.14
Phase 2 N=200 Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
Alzheimer's Disease · Dementia · Memory Loss
Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67
N/A N=5 Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Alzheimer's Disease · Depression
Primary: Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change. — 2; 0; 1; 2 Participants
Phase 2 N=125 Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Alzheimer Disease · Cognitive Decline
Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio
Phase 2 N=31 Memory and Insulin in Early Alzheimer's Disease
Alzheimer's Disease
Primary: fMRI Measure of Hippocampal Activation — 36.4; 41.3 percentage of active voxels